AMPLIA THERAPEUTICS LIMITED — Director's Dealing 2021

Dec 20, 2021

ABN 16 165 160 841

21 December 2021

==> picture [165 x 52] intentionally omitted <==

ASX RELEASE

Change of Director’s Interest Notice – Appendix 3Y: Jane Bell

Appendix 3Y Change of Director’s Interest Notice for Mrs. Jane Bell is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

• End -

For further information:

Andrew J. Cooke Company Secretary andrew@ampliatx.com www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Level 21, 90 Collins Street, Melbourne VIC 3000

Email info@ampliatx.com

www.ampliatx.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity AMPLIA THERAPEUTICS LIMITED ABN 16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

	Name of Director	Name of Director	Jane Catherine Bell
	Date of last notice		6 September 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Note: In the case of a company, interests which com	Note: In the case of a company, interests which com	Note: In the case of a company, interests which com	Note: In the case of a company, interests which com	e within paragraph (i) of the definition of “notifiable interest of a director” should be	e within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
	Direct or indirect interest				Direct
	Nature of indirect interest
	(including registered holder)Note: Provide details of the circumstances givingrise to the relevant interest.
	Date of change
		ange			15 and 20 December 2021
	No. of securities held prior tochange	securitie	s held prior to		Jane Bell
					277,163 Ordinary Shares
					Mrs Jane Catherine Bell & Mr Geoffrey Bell <SchoonerSuper Fund A/C>593,914 Ordinary Shares
	Class				Ordinary SharesATXO Listed Options Ex Price $0.28 Exp 31 Dec 2023
	Number acquired				15 December 2021:Ordinary Shares – 217,770ATXO Listed Options – 72,59020 December 2021:OrdinaryShares – 714,285

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	Nil
Value/Consideration	15 Dec 2021 Entitlement Offer - $0.18 per share (with free
Note: If consideration is non-cash, provide detailsand estimated valuation	attaching ATXO Listed Options on 1 for 3 basis)
	20 Dec 2021 On Market Trade - $0.145 per share
No. of securities held after change	Mrs Jane Catherine Bell
	346,454 Ordinary Shares
	23,097 ATXO Listed Options Ex Price $0.28 Exp 31 Dec 2023
	Mrs Jane Catherine Bell & Mr Geoffrey Bell <Schooner
	Super Fund A/C>
	1,456,678 Ordinary Shares
	49,493 ATXO Listed Options Ex Price $0.28 Exp 31 Dec 2023
Nature of change	15 December 2021 – Participation in Entitlement Offer
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in buy-	20 December 2021 - On-Market trade
back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Nil
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation
Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow thetrade to proceed during this period?
If prior written clearance was provided, on what date wasthis provided?

21 December 2021

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3